Adjuvant Chemotherapy in Rectal Cancer after Chemoradiotherapy.
Fiche publication
Date publication
février 2016
Journal
Clinical oncology (Royal College of Radiologists (Great Britain))
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOUSTANI Jihane
Tous les auteurs :
Boustani J, Caubet M, Bosset JF
Lien Pubmed
Résumé
The aim of this overview was to investigate whether adjuvant chemotherapy has a favourable effect on the outcome of patients with rectal cancer who had preoperative (chemo)radiotherapy. A review of randomised clinical trials that allocated patients between fluorouracil-based and observation or between fluorouracil-based and oxaliplatin-based adjuvant chemotherapy after preoperative (chemo)radiotherapy was carried out, including their corresponding meta-analyses. None of the five randomised trials has shown a significant benefit of fluorouracil-based adjuvant chemotherapy for overall survival or disease-free survival. Also, the three corresponding meta-analyses failed to show a benefit of adjuvant treatment. Of three randomised trials - two phase III and one phase II with a 3-year disease-free survival end point - two showed a small benefit of adding oxaliplatin to fluorouracil, one failed. The corresponding meta-analyses showed that the pooled difference was not significant. In conclusion, the use of postoperative 5-fluorouracil-based chemotherapy with or without oxaliplatin in patients with rectal cancer after preoperative (chemo)radiotherapy is not scientifically proven.
Mots clés
Adjuvant chemotherapy, meta-analysis, preoperative chemoradiotherapy, preoperative radiotherapy, rectal cancer
Référence
Clin Oncol (R Coll Radiol). 2016 02;28(2):140-145